Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis
Lp(a) testing in the primary prevention population to reclassify CVD risk and treatment is cost-saving and warranted to prevent CVD.
Authors
- Magdalena Daccord
- Kausik Kumar Ray (ORCID: https://orcid.org/0000-0003-0508-0954)
- Marius Geantă (ORCID: https://orcid.org/0000-0003-1510-8885)
- Zanfina Ademi (ORCID: https://orcid.org/0000-0002-0625-3522)
- Albert Wiegman (ORCID: https://orcid.org/0000-0001-6223-5671)
- Paola Coral
- Mariko Harada‐Shiba (ORCID: https://orcid.org/0000-0002-7600-2059)
- George Thanassoulis (ORCID: https://orcid.org/0000-0002-9930-7189)
- Pia R. Kamstrup
- Jean-Luc Eiselé
- Christie Mitchell Ballantyne (ORCID: https://orcid.org/0000-0002-6432-1730)
- Raul Dias Santos (ORCID: https://orcid.org/0000-0002-9860-6582)
- Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
- Iñaki Gutiérrez‐Ibarluzea (ORCID: https://orcid.org/0000-0002-4080-7963)
- Zhenyue Chen (ORCID: https://orcid.org/0000-0002-4329-5940)
- Jedidiah I Morton (ORCID: https://orcid.org/0000-0002-3231-5758)
- Samia Mora (ORCID: https://orcid.org/0000-0001-6283-0980)
- Gerald F. Watts (ORCID: https://orcid.org/0000-0003-2276-1524)
- Børge Grønne Nordestgaard (ORCID: https://orcid.org/0000-0002-1954-7220)
- Erik S.G. Stroes (ORCID: https://orcid.org/0000-0001-9555-6260)
- Florian Kronenberg (ORCID: https://orcid.org/0000-0003-2229-1120)
- Michal Vráblík (ORCID: https://orcid.org/0000-0002-7226-1926)
- Nicola Bedlington
- Tobias Silberzahn
- Marc Rijken
- Bogi Eliasen
Institutions
- Brigham and Women's Hospital (US)
- Baker Heart and Diabetes Institute (AU)
- Innsbruck Medical University (AT)
- Baylor College of Medicine (US)
- Charles University (CZ)
- Royal Perth Hospital (AU)
- Copenhagen Institute for Futures Studies (DK)
- Hospital Israelita Albert Einstein (BR)
- Basque Government (ES)
- Ruijin Hospital (CN)
- Gentofte Hospital (DK)
- McGill Genome Centre (CA)
- Universidad Fraternidad de Agrupaciones Santo Tomás de Aquino (AR)
- Canon Foundation in Europe (NL)
- Ministerul Cercetării și Inovării (RO)
- Amsterdam University Medical Centers (NL)
- General University Hospital in Prague (CZ)
- Imperial College London (GB)
- Monash University (AU)
- University of Amsterdam (NL)
- Osaka University of Pharmaceutical Sciences (JP)
- World Heart Federation (CH)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2025.120447
- Citations
- 13
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 26.08
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- CSL Behring
- Regeneron Pharmaceuticals
- UK Research and Innovation
- Anthera
- InfraRedx
- National Institute for Health and Care Research
- National Heart Foundation of Australia
- Monash University
- Silence Therapeutics
- Esperion Therapeutics
- Medical Research Council
- National Health and Medical Research Council